Raday Gilead has made a significant disclosure regarding changes in beneficial ownership, as reported in its recent SEC filing. This event is crucial as it may indicate shifts in leadership or shareholder dynamics within the company, which could influence its operational strategies and market positioning.

Background

Raday Gilead is categorized under the pharmaceutical industry, specifically focusing on the development of innovative treatments. The company is identified by its Central Index Key (CIK) number 0002113137. Recent filings include the latest Form 4 submitted on October 6, 2026, and prior filings on July 13, 2026, April 22, 2026, and March 18, 2026.

What the Filing Says

The October 6 filing indicates a change in beneficial ownership, although specific details regarding the nature of the changes were not disclosed. The period of the report is noted as October 1, 2026.

Impact

This change in beneficial ownership may affect various stakeholders, including current shareholders, potential investors, and company management. The pharmaceutical preparations industry, which includes competitors like RedHill Biopharma Ltd., may also feel the ripple effects of this development.

What's Next

The filing does not say what happens next.

Details of the Filing

The Form 4 filed by Raday Gilead on October 6, 2026, indicates that the report covers the period ending October 1, 2026. This filing is particularly important as it provides insights into the changes in beneficial ownership, which may involve transactions such as acquisitions or disposals of shares by key insiders.

Company Information

Raday Gilead is headquartered at 21 Ha'Arba'a Street, Tel Aviv, L3 64739, Israel, with a contact number of 972-3-541-3131. The company is registered under the Central Index Key (CIK) number 0002113137, and its SEC file number is 001-35773.

Related Filings

In addition to the recent filing, Raday Gilead has submitted several other filings earlier in 2026, including those on July 13, April 22, and March 18. These documents can provide further context regarding the company's transactions and ownership changes over the year.

Absence of Specific Details

The filing does not provide specific details regarding the identity of the individuals involved in the changes in beneficial ownership or the exact nature of the transactions. This lack of information leaves stakeholders with limited insights into the motivations behind these changes.